Eiger says liquid SC exendin 9-39 may allow for lower and less frequent dosing
Eiger BioPharmaceuticals announced "positive" data from the Phase 2 multiple-ascending dose study evaluating subcutaneous exendin 9-39 in post-bariatric surgical patients who experience dangerously low, postprandial blood glucose levels, known as post-bariatric hypoglycemia. A liquid and a lyophilized formulation of SC exendin 9-39 were evaluated in the MAD study. Results available from 19 of 20 patients were presented at the 2017 American Diabetes Association meeting. "We are very encouraged by these results and our progress with SC exendin 9-39 in PBH patients, including data using Eiger's new proprietary liquid formulation of SC exendin 9-39. Liquid SC exendin 9-39 offers a more patient friendly formulation, and may provide an opportunity for lower and less frequent dosing due to enhanced drug exposure. Exendin 9-39 is the first potential targeted therapy for patients suffering from PBH, a significant unmet medical need," said Lisa Porter, MD, Senior Vice President, Metabolic Diseases at Eiger.